Upadacitinib 15 mg was shown to be superior to placebo for achieving sustained remission in giant cell arteritis, according to data presented at ACR Convergence 2024. The study included patients aged 50 years and older with new-onset or relapsing GCA. Sustained remission at 52 weeks was the primary endpoint, with the 15-mg formulation of upadacitinib significantly outperforming placebo. The drug’s efficacy was consistent across various patient subgroups based on age, sex, glucocorticoid use, and other factors. Overall, the results support the broad efficacy of upadacitinib 15 mg in the treatment of GCA.
Source link
Upadacitinib shows ‘broad efficacy’ across patient subgroups in giant cell arteritis
